{"id":"https://openalex.org/W7225318587","doi":"https://doi.org/10.1126/science.aej9836","title":"GLP-1 receptor agonists in addiction therapy","display_name":"GLP-1 receptor agonists in addiction therapy","publication_year":2026,"publication_date":"2026-11-05","ids":{"openalex":"https://openalex.org/W7225318587","doi":"https://doi.org/10.1126/science.aej9836","pmid":"https://pubmed.ncbi.nlm.nih.gov/42986956"},"language":"en","primary_location":{"id":"doi:10.1126/science.aej9836","doi":"https://doi.org/10.1126/science.aej9836","is_oa":false,"landing_page_url":"https://doi.org/10.1126/science.aej9836","pdf_url":null,"source":{"id":"https://openalex.org/S3880285","display_name":"Science","issn_l":"0036-8075","issn":["0036-8075","0193-4511","1095-9203"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","erih-plus","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315823","host_organization_name":"American Association for the Advancement of Science","host_organization_lineage":["https://openalex.org/P4310315823"],"host_organization_lineage_names":["American Association for the Advancement of Science"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Science","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5002969658","display_name":"Nora D. Volkow","orcid":"https://orcid.org/0000-0001-6668-0908","observed_orcids":["https://orcid.org/0000-0001-6668-0908"]},"institutions":[{"id":"https://openalex.org/I1327069482","display_name":"National Institute on Drug Abuse","ror":"https://ror.org/00fq5cm18","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I1327069482"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nora D. Volkow","raw_affiliation_strings":["National Institute on Drug Abuse, Bethesda, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"National Institute on Drug Abuse, Bethesda, MD, USA","institution_ids":["https://openalex.org/I1327069482"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5056279737","display_name":"Eric M. Wargo","orcid":"https://orcid.org/0000-0002-9890-0116","observed_orcids":["https://orcid.org/0000-0002-9890-0116"]},"institutions":[{"id":"https://openalex.org/I1327069482","display_name":"National Institute on Drug Abuse","ror":"https://ror.org/00fq5cm18","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I1327069482"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Eric M. Wargo","raw_affiliation_strings":["National Institute on Drug Abuse, Bethesda, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"National Institute on Drug Abuse, Bethesda, MD, USA","institution_ids":["https://openalex.org/I1327069482"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I1327069482"],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"394","issue":"6824","first_page":"610","last_page":"611"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.6592000126838684,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.6592000126838684,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10043","display_name":"Substance Abuse Treatment and Outcomes","score":0.13670000433921814,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12539","display_name":"Pharmacology and Obesity Treatment","score":0.04659999907016754,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/glp-1-receptor-agonists","display_name":"GLP-1 receptor agonists","score":1.0},{"id":"https://openalex.org/keywords/addiction-treatment","display_name":"addiction treatment","score":0.7390000224113464},{"id":"https://openalex.org/keywords/substance-use-disorders","display_name":"substance use disorders","score":0.7799999713897705},{"id":"https://openalex.org/keywords/drug-therapy","display_name":"pharmacotherapy","score":0.40799999237060547}],"concepts":[{"id":"https://openalex.org/C48856860","wikidata":"https://www.wikidata.org/wiki/Q12029","display_name":"Addiction","level":2,"score":0.6955000162124634},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6092000007629395},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5529999732971191},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.4244000017642975},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.41830000281333923},{"id":"https://openalex.org/C500440147","wikidata":"https://www.wikidata.org/wiki/Q701216","display_name":"Pharmacotherapy","level":2,"score":0.3327000141143799},{"id":"https://openalex.org/C60644358","wikidata":"https://www.wikidata.org/wiki/Q128570","display_name":"Bioinformatics","level":1,"score":0.2964000105857849},{"id":"https://openalex.org/C100776233","wikidata":"https://www.wikidata.org/wiki/Q2532492","display_name":"Bridge (graph theory)","level":2,"score":0.28839999437332153},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.28040000796318054},{"id":"https://openalex.org/C169885649","wikidata":"https://www.wikidata.org/wiki/Q55190072","display_name":"Addiction medicine","level":3,"score":0.27309998869895935},{"id":"https://openalex.org/C2779473830","wikidata":"https://www.wikidata.org/wiki/Q1540899","display_name":"MEDLINE","level":2,"score":0.27160000801086426},{"id":"https://openalex.org/C169760540","wikidata":"https://www.wikidata.org/wiki/Q207011","display_name":"Neuroscience","level":1,"score":0.2705000042915344},{"id":"https://openalex.org/C160735492","wikidata":"https://www.wikidata.org/wiki/Q31207","display_name":"Health care","level":2,"score":0.25040000677108765}],"mesh":[{"descriptor_ui":"D000067757","descriptor_name":"Glucagon-Like Peptide-1 Receptor","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D000077270","descriptor_name":"Exenatide","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000077270","descriptor_name":"Exenatide","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000097789","descriptor_name":"Glucagon-Like Peptide-1 Receptor Agonists","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000097789","descriptor_name":"Glucagon-Like Peptide-1 Receptor Agonists","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016739","descriptor_name":"Behavior, Addictive","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D019966","descriptor_name":"Substance-Related Disorders","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D052216","descriptor_name":"Glucagon-Like Peptide 1","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D052216","descriptor_name":"Glucagon-Like Peptide 1","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1126/science.aej9836","doi":"https://doi.org/10.1126/science.aej9836","is_oa":false,"landing_page_url":"https://doi.org/10.1126/science.aej9836","pdf_url":null,"source":{"id":"https://openalex.org/S3880285","display_name":"Science","issn_l":"0036-8075","issn":["0036-8075","0193-4511","1095-9203"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","erih-plus","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315823","host_organization_name":"American Association for the Advancement of Science","host_organization_lineage":["https://openalex.org/P4310315823"],"host_organization_lineage_names":["American Association for the Advancement of Science"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Science","raw_type":"journal-article"},{"id":"pmid:42986956","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42986956","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Science (New York, N.Y.)","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":13,"referenced_works":["https://openalex.org/W2283026346","https://openalex.org/W2596879656","https://openalex.org/W2605039244","https://openalex.org/W3202781181","https://openalex.org/W4399094063","https://openalex.org/W4407009786","https://openalex.org/W4407392321","https://openalex.org/W4408891926","https://openalex.org/W4412723339","https://openalex.org/W7124291437","https://openalex.org/W7126196542","https://openalex.org/W7160062099","https://openalex.org/W7167249214"],"related_works":["https://openalex.org/W7125119344","https://openalex.org/W7133567540","https://openalex.org/W4416847720","https://openalex.org/W7211420799","https://openalex.org/W7092542061","https://openalex.org/W4410760868","https://openalex.org/W4414994896","https://openalex.org/W7126106183","https://openalex.org/W3200755535","https://openalex.org/W4409751215"],"abstract_inverted_index":{"Use":[0],"of":[1],"GLP-1-based":[2],"therapies":[3],"for":[4],"addiction":[5],"could":[6],"provide":[7],"a":[8],"bridge":[9],"toward":[10],"whole-person":[11],"health":[12],"care.":[13]},"counts_by_year":[],"updated_date":"2026-11-11T12:16:26.678958","created_date":"2026-11-06T00:00:00"}